Of what value genomics in colorectal cancer? Opportunities and challenges

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1538-1539

  Johnston, Patrick G ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN; THYMIDYLATE SYNTHASE; RNA; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; DNA FINGERPRINTING; DNA MICROARRAY; EDITORIAL; GENOMICS; HETEROZYGOSITY; HUMAN; LYMPH NODE; METASTASIS; MOLECULAR BIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; CANCER STAGING; COLORECTAL TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; NOTE; PATHOLOGY; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RNA; TUMOR MARKERS, BIOLOGICAL;

EID: 2442640575     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.945     Document Type: Editorial

References (14)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics 2002. Ca Cancer J Clin 52:23-47, 2002
2. Van Cutsem E, Dicato M, Wils J: Recent advances in the management of colorectal cancer. Eur J Cancer 37:2302-2309, 2001
3. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs-Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
4. Doulliard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for colorectal cancer: A multicentred randomised trial. Lancet 355:1041-1047, 2000
5. Saltz LB, Cox JV, Blanke C, et al: Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
6. Goldberg R, Sargeant DJ, Roscoe F, et al: A randomised controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
7. International multi-centered pooled analysis of B2 colon cancer trials (Impact B2) investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363, 1999
8. Fisher ER, Sass R, Palekar A, et al: Duke's Classification revisited. Cancer 64:2354-2360, 1989
9. Astler VB, Cioller FA: The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 139:846-852, 1954
10. McLeod HL, Murray GI: Tumor markers of prognosis in colorectal cancer. Br J Cancer 79:191-203, 1999
11. Watanabe T, Wu TT, Catalano PJ, et al: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344:196-1206, 2001
12. Allegra CJ, Paik S, Colangelo LS, et al: Prognostic value of thymidylate synthase Ki-67 and p53 in patients with Dukes' B and C colon cancer and NCI-NSABP collaborative study. J Clin Oncol 21:241-250, 2003
13. Longley DB, Harkin DP, Johnston PG: 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338, 2003
14. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes B colon cancer. J Clin Oncol 22:1564-1571, 2004